anurajms/meta_analysis huggingface dataset:
MESH terms:
Droperidol for psychosis‐induced aggression or agitation
1. Acute Disease; 2. Aggression [drug effects]; 3. Antipsychotic Agents [*therapeutic use]; 4. Benzodiazepines [therapeutic use]; 5. Droperidol [*therapeutic use]; 6. Haloperidol [therapeutic use]; 7. Midazolam [therapeutic use]; 8. Olanzapine; 9. Psychomotor Agitation [drug therapy]; 10. Psychotic Disorders [*drug therapy]; 11. Randomized Controlled Trials as Topic;
MESH terms:
Haloperidol for long‐term aggression in psychosis
1. Aggression [*drug effects, psychology]; 2. Antipsychotic Agents [*administration & dosage]; 3. Benzodiazepines [administration & dosage]; 4. Clozapine [administration & dosage]; 5. Drug Administration Schedule; 6. Haloperidol [*administration & dosage]; 7. Olanzapine; 8. Psychotic Disorders [*complications, drug therapy]; 9. Randomized Controlled Trials as Topic; 10. Schizophrenia [*complications, drug therapy];
MESH terms:
Haloperidol plus promethazine for psychosis‐induced aggression
1. Aggression [*drug effects, psychology]; 2. Benzodiazepines [therapeutic use]; 3. Drug Therapy, Combination; 4. Haloperidol [*therapeutic use]; 5. Lorazepam [therapeutic use]; 6. Midazolam [therapeutic use]; 7. Promethazine [*therapeutic use]; 8. Psychomotor Agitation; 9. Psychotic Disorders [*drug therapy, psychology]; 10. Randomized Controlled Trials as Topic; 11. Restraint, Physical [statistics & numerical data];
MESH terms:
Valproate for schizophrenia
1. Antimanic Agents [*therapeutic use]; 2. Antipsychotic Agents [therapeutic use]; 3. Randomized Controlled Trials as Topic; 4. Schizophrenia [*drug therapy]; 5. Valproic Acid [*therapeutic use];
MESH terms:
Antihypertensive withdrawal for the prevention of cognitive decline
1. *Antihypertensive Agents; 2. *Withholding Treatment; 3. Blood Pressure [physiology]; 4. Cognition [drug effects]; 5. Cognitive Dysfunction [*prevention & control]; 6. Dementia [prevention & control]; 7. Randomized Controlled Trials as Topic; 8. Stroke; 9. Time Factors;
MESH terms:
Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults
1. Agoraphobia [complications, *therapy]; 2. Antidepressive Agents [*therapeutic use]; 3. Benzodiazepines [*therapeutic use]; 4. Panic Disorder [complications, *therapy]; 5. Patient Dropouts [statistics & numerical data]; 6. Psychotherapy [*methods]; 7. Randomized Controlled Trials as Topic; 8. Remission Induction; 9. Selective Serotonin Reuptake Inhibitors [*therapeutic use];
MESH terms:
Bifeprunox versus placebo for schizophrenia
1. Antipsychotic Agents [adverse effects, *therapeutic use]; 2. Benzoxazoles [adverse effects, *therapeutic use]; 3. Drug Approval; 4. Intention to Treat Analysis; 5. Piperazines [adverse effects, *therapeutic use]; 6. Randomized Controlled Trials as Topic; 7. Schizophrenia [*drug therapy]; 8. Schizophrenic Psychology; 9. United States; 10. United States Food and Drug Administration;
MESH terms:
Psychological therapies for children and adolescents exposed to trauma
1. Aggression [psychology]; 2. Child Abuse, Sexual [psychology]; 3. Cognitive Behavioral Therapy; 4. Desensitization, Psychologic; 5. Exposure to Violence [psychology]; 6. Family Therapy; 7. Interview, Psychological; 8. Psychotherapy [*methods]; 9. Psychotherapy, Psychodynamic; 10. Randomized Controlled Trials as Topic; 11. Stress Disorders, Post-Traumatic [*prevention & control, psychology]; 12. Treatment Outcome; 13. War Exposure;
MESH terms:
Continuation and maintenance treatments for depression in older people
1. Antidepressive Agents [*therapeutic use]; 2. Combined Modality Therapy [methods]; 3. Depression [*therapy]; 4. Maintenance Chemotherapy [methods]; 5. Psychotherapy [*methods]; 6. Randomized Controlled Trials as Topic; 7. Secondary Prevention;
MESH terms:
Topiramate for acute affective episodes in bipolar disorder in adults
1. Affective Disorders, Psychotic [*drug therapy]; 2. Antimanic Agents [*therapeutic use]; 3. Bipolar Disorder [*psychology]; 4. Bupropion [therapeutic use]; 5. Depressive Disorder [drug therapy]; 6. Fructose [*analogs & derivatives, therapeutic use]; 7. Randomized Controlled Trials as Topic; 8. Topiramate;
MESH terms:
Cognitive behavioural therapy (CBT), third‐wave CBT and interpersonal therapy (IPT) based interventions for preventing depression in children and adolescents
1. Depression [diagnosis, *prevention & control]; 2. Depressive Disorder [diagnosis, *prevention & control]; 3. Program Evaluation; 4. Psychotherapy [methods]; 5. Randomized Controlled Trials as Topic;
MESH terms:
Routine use of patient reported outcome measures (PROMs) for improving treatment of common mental health disorders in adults
1. *Patient Outcome Assessment; 2. Antipsychotic Agents [therapeutic use]; 3. Feedback; 4. Mental Disorders [psychology, *therapy]; 5. Quality of Life; 6. Randomized Controlled Trials as Topic; 7. Suicidal Ideation;
MESH terms:
Fluphenazine (oral) versus atypical antipsychotics for schizophrenia
1. Administration, Oral; 2. Amisulpride; 3. Antipsychotic Agents [adverse effects, *therapeutic use]; 4. Benzodiazepines [adverse effects, therapeutic use]; 5. Fluphenazine [adverse effects, *therapeutic use]; 6. Olanzapine; 7. Quetiapine Fumarate [adverse effects, therapeutic use]; 8. Randomized Controlled Trials as Topic; 9. Risperidone [adverse effects, therapeutic use]; 10. Schizophrenia [*drug therapy]; 11. Sulpiride [adverse effects, analogs & derivatives, therapeutic use]; 12. Treatment Outcome;
MESH terms:
Pharmacological interventions for clozapine‐induced sinus tachycardia
1. Antipsychotic Agents [*adverse effects]; 2. Clozapine [*adverse effects]; 3. Schizophrenia [drug therapy]; 4. Tachycardia, Sinus [*chemically induced, *drug therapy];
MESH terms:
Psychosocial interventions for self‐harm in adults
1. Cognitive Behavioral Therapy [methods]; 2. Depression [therapy]; 3. Personality Disorders [therapy]; 4. Problem Solving; 5. Psychotherapy [*methods]; 6. Randomized Controlled Trials as Topic; 7. Self-Injurious Behavior [psychology, *therapy]; 8. Suicidal Ideation; 9. Theory of Mind;
MESH terms:
Chlorpromazine versus reserpine for schizophrenia
1. Antipsychotic Agents [adverse effects, *therapeutic use]; 2. Chlorpromazine [adverse effects, *therapeutic use]; 3. Randomized Controlled Trials as Topic; 4. Reserpine [adverse effects, *therapeutic use]; 5. Schizophrenia [*drug therapy];
MESH terms:
Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta‐analysis
1. Agoraphobia [psychology, *therapy]; 2. Panic Disorder [psychology, *therapy]; 3. Psychotherapy [*methods]; 4. Randomized Controlled Trials as Topic;
MESH terms:
Chlorpromazine versus atypical antipsychotic drugs for schizophrenia
1. Antipsychotic Agents [*therapeutic use]; 2. Benzodiazepines [therapeutic use]; 3. Chlorpromazine [*therapeutic use]; 4. Olanzapine; 5. Quetiapine Fumarate [therapeutic use]; 6. Randomized Controlled Trials as Topic; 7. Risperidone [therapeutic use]; 8. Schizophrenia [*drug therapy];
MESH terms:
Psychological therapies for post‐traumatic stress disorder and comorbid substance use disorder
1. Alcoholism [diagnosis, therapy]; 2. Psychotherapy [*methods]; 3. Randomized Controlled Trials as Topic; 4. Stress Disorders, Post‐Traumatic [diagnosis, *therapy]; 5. Substance‐Related Disorders [diagnosis, *therapy];
MESH terms:
Therapist‐supported Internet cognitive behavioural therapy for anxiety disorders in adults
1. Agoraphobia [therapy]; 2. Anxiety Disorders [*therapy]; 3. Cognitive Behavioral Therapy [*methods]; 4. Depressive Disorder [therapy]; 5. *Internet; 6. Phobic Disorders [therapy]; 7. Randomized Controlled Trials as Topic;
MESH terms:
Interventions for preventing delirium in hospitalised non‐ICU patients
1. *Hospitalization; 2. Anesthesia, Epidural; 3. Anesthetics, Inhalation; 4. Antipsychotic Agents [therapeutic use]; 5. Cholinesterase Inhibitors [therapeutic use]; 6. Cytidine Diphosphate Choline [administration & dosage]; 7. Delirium [*prevention & control]; 8. Melatonin [agonists, therapeutic use]; 9. Nootropic Agents [administration & dosage]; 10. Randomized Controlled Trials as Topic;
MESH terms:
Antiglucocorticoid and related treatments for psychosis
1. Dehydroepiandrosterone [therapeutic use]; 2. Dexamethasone [therapeutic use]; 3. Glucocorticoids [*antagonists & inhibitors]; 4. Hypothalamo‐Hypophyseal System; 5. Ketoconazole [therapeutic use]; 6. Mifepristone [adverse effects, therapeutic use]; 7. Pituitary‐Adrenal System; 8. Psychotic Disorders [*drug therapy]; 9. Randomized Controlled Trials as Topic;
MESH terms:
Statins for the prevention of dementia
1. Alzheimer Disease [prevention & control]; 2. Anticholesteremic Agents [*therapeutic use]; 3. Cognition [drug effects]; 4. Dementia [*prevention & control]; 5. Hydroxymethylglutaryl‐CoA Reductase Inhibitors [therapeutic use]; 6. Pravastatin [therapeutic use]; 7. Randomized Controlled Trials as Topic; 8. Simvastatin [therapeutic use];
MESH terms:
Interventions for self‐harm in children and adolescents
1. Anti-Anxiety Agents [therapeutic use]; 2. Antidepressive Agents [*therapeutic use]; 3. Antipsychotic Agents [*therapeutic use]; 4. Behavior Therapy [methods]; 5. Family Therapy; 6. Patient Compliance [statistics & numerical data]; 7. Problem Solving; 8. Psychotherapy [*methods]; 9. Psychotherapy, Group; 10. Randomized Controlled Trials as Topic; 11. Recurrence; 12. Secondary Prevention [methods]; 13. Self-Injurious Behavior [*prevention & control, psychology]; 14. Suicide Prevention; 15. Theory of Mind;
MESH terms:
Zuclopenthixol versus placebo for schizophrenia
1. Antipsychotic Agents [adverse effects, therapeutic use]; 2. Clopenthixol [adverse effects, analogs & derivatives, *therapeutic use]; 3. Randomized Controlled Trials as Topic; 4. Schizophrenia [*drug therapy];
MESH terms:
Pharmacotherapy for chronic cognitive impairment in traumatic brain injury
1. Atomoxetine Hydrochloride [therapeutic use]; 2. Benzhydryl Compounds [therapeutic use]; 3. Brain Injuries [*complications]; 4. Chronic Disease; 5. Cognition [drug effects]; 6. Cognition Disorders [*drug therapy, etiology]; 7. Modafinil; 8. Nootropic Agents [*therapeutic use]; 9. Piperidines [therapeutic use]; 10. Randomized Controlled Trials as Topic; 11. Rivastigmine [therapeutic use];
MESH terms:
Asenapine versus placebo for schizophrenia
1. Antipsychotic Agents [adverse effects, *therapeutic use]; 2. Dibenzocycloheptenes; 3. Heterocyclic Compounds, 4 or More Rings [adverse effects, *therapeutic use]; 4. Psychotic Disorders [drug therapy]; 5. Randomized Controlled Trials as Topic; 6. Schizophrenia [*drug therapy]; 7. Treatment Outcome;
MESH terms:
Lithium for schizophrenia
1. Antipsychotic Agents [*therapeutic use]; 2. Drug Therapy, Combination; 3. Lithium Compounds [*therapeutic use]; 4. Patient Dropouts [statistics & numerical data]; 5. Randomized Controlled Trials as Topic; 6. Schizophrenia [*drug therapy];
MESH terms:
Cognitive behavioural therapy (brief versus standard duration) for schizophrenia
1. *Psychotherapy, Brief; 2. Cognitive Behavioral Therapy [*methods]; 3. Schizophrenia [*therapy]; 4. Time Factors;
MESH terms:
Rivastigmine for Alzheimer's disease
1. Alzheimer Disease [*drug therapy]; 2. Caregivers [psychology]; 3. Cholinesterase Inhibitors [*administration & dosage, adverse effects]; 4. Cognition Disorders [drug therapy]; 5. Drug Administration Schedule; 6. Phenylcarbamates [*administration & dosage, adverse effects]; 7. Randomized Controlled Trials as Topic; 8. Rivastigmine; 9. Severity of Illness Index;
MESH terms:
Endoscopic third ventriculostomy (ETV) for idiopathic normal pressure hydrocephalus (iNPH)
1. Cerebrospinal Fluid Shunts [methods]; 2. Hydrocephalus, Normal Pressure [*surgery]; 3. Randomized Controlled Trials as Topic; 4. Third Ventricle [*surgery]; 5. Ventriculostomy [adverse effects, *methods];
MESH terms:
Individual psychological therapy in the outpatient treatment of adults with anorexia nervosa
1. Anorexia Nervosa [psychology, *therapy]; 2. Cognitive Behavioral Therapy [methods]; 3. Psychotherapy [*methods]; 4. Psychotherapy, Psychodynamic [methods]; 5. Randomized Controlled Trials as Topic;
MESH terms:
Pharmacological interventions for self‐harm in adults
1. Anticonvulsants [therapeutic use]; 2. Antidepressive Agents [*therapeutic use]; 3. Antipsychotic Agents [*therapeutic use]; 4. Fluphenazine [therapeutic use]; 5. Lithium Compounds [therapeutic use]; 6. Randomized Controlled Trials as Topic; 7. Recurrence; 8. Self-Injurious Behavior [*drug therapy];
MESH terms:
Treatments for delusional disorder
1. *Cognitive Behavioral Therapy; 2. Psychotherapy; 3. Randomized Controlled Trials as Topic; 4. Schizophrenia, Paranoid [*therapy]; 5. Self Concept;
MESH terms:
Opioids for agitation in dementia
1. Analgesics, Opioid [*therapeutic use]; 2. Dementia [*psychology]; 3. Psychomotor Agitation [*drug therapy];
MESH terms:
Augmentation of cognitive and behavioural therapies (CBT) with d‐cycloserine for anxiety and related disorders
1. Anxiety Disorders [*therapy]; 2. Cognitive Behavioral Therapy [*methods]; 3. Combined Modality Therapy [methods]; 4. Cycloserine [*therapeutic use]; 5. Randomized Controlled Trials as Topic;
MESH terms:
Psychoeducation for siblings of people with severe mental illness
1. *Mental Disorders; 2. Adaptation, Psychological; 3. Caregivers [*education, psychology]; 4. Mental Health [*education]; 5. Quality of Life; 6. Randomized Controlled Trials as Topic; 7. Siblings [*psychology];
MESH terms:
Aerobic exercise to improve cognitive function in older people without known cognitive impairment
1. Cognition [*physiology]; 2. Cognition Disorders [prevention & control]; 3. Exercise [*physiology]; 4. Memory [physiology]; 5. Oxygen Consumption [physiology]; 6. Physical Fitness [*physiology]; 7. Randomized Controlled Trials as Topic;
MESH terms:
Latrepirdine for Alzheimer's disease
1. Alzheimer Disease [*drug therapy, psychology]; 2. Behavior [drug effects]; 3. Cognition [drug effects]; 4. Indoles [adverse effects, *therapeutic use]; 5. Nootropic Agents [adverse effects, *therapeutic use]; 6. Randomized Controlled Trials as Topic;
MESH terms:
Debriefing interventions for the prevention of psychological trauma in women following childbirth
1. Delivery, Obstetric [*psychology]; 2. Depression [prevention & control]; 3. Narrative Therapy [*methods]; 4. Parturition [*psychology]; 5. Postpartum Period [*psychology]; 6. Randomized Controlled Trials as Topic; 7. Stress Disorders, Post‐Traumatic [*prevention & control]; 8. Stress, Psychological [*prevention & control];
MESH terms:
Psychoeducation (brief) for people with serious mental illness
1. *Awareness; 2. Cognitive Behavioral Therapy; 3. Medication Adherence [statistics & numerical data]; 4. Patient Education as Topic [*methods]; 5. Psychotherapy, Brief [*methods]; 6. Quality of Life; 7. Randomized Controlled Trials as Topic; 8. Reality Therapy [methods]; 9. Recurrence; 10. Schizophrenia [*therapy]; 11. Schizophrenic Psychology;
MESH terms:
Perphenazine for schizophrenia
1. Antipsychotic Agents [adverse effects, *therapeutic use]; 2. Mental Disorders [drug therapy]; 3. Perphenazine [adverse effects, *therapeutic use]; 4. Randomized Controlled Trials as Topic; 5. Schizophrenia [*drug therapy];
MESH terms:
Cholinesterase inhibitors for rarer dementias associated with neurological conditions
1. CADASIL [*drug therapy]; 2. Cholinesterase Inhibitors [*therapeutic use]; 3. Cognition Disorders [drug therapy]; 4. Frontotemporal Dementia [*drug therapy]; 5. Huntington Disease [*drug therapy]; 6. Multiple Sclerosis [complications, *drug therapy]; 7. Nootropic Agents [*therapeutic use]; 8. Randomized Controlled Trials as Topic;
MESH terms:
Cognitive behavioural therapy for anxiety disorders in children and adolescents
1. Anxiety Disorders [*therapy]; 2. *Cognitive Behavioral Therapy; 3. Randomized Controlled Trials as Topic;
MESH terms:
Fluphenazine decanoate (depot) and enanthate for schizophrenia
1. Administration, Oral; 2. Antipsychotic Agents [administration & dosage, *therapeutic use]; 3. Delayed‐Action Preparations [administration & dosage, therapeutic use]; 4. Fluphenazine [administration & dosage, *analogs & derivatives, therapeutic use]; 5. Injections, Intramuscular; 6. Randomized Controlled Trials as Topic; 7. Schizophrenia [drug therapy];
MESH terms:
Pharmacotherapy for anxiety and comorbid alcohol use disorders
1. Alcohol-Related Disorders [*drug therapy, epidemiology]; 2. Anxiety [*drug therapy, epidemiology]; 3. Anxiety Disorders [drug therapy, epidemiology]; 4. Buspirone [therapeutic use]; 5. Comorbidity; 6. Desipramine [therapeutic use]; 7. Paroxetine [therapeutic use]; 8. Phobia, Social [drug therapy, epidemiology]; 9. Publication Bias; 10. Randomized Controlled Trials as Topic; 11. Selective Serotonin Reuptake Inhibitors [*therapeutic use]; 12. Sertraline [therapeutic use]; 13. Stress Disorders, Post-Traumatic [drug therapy, epidemiology];
MESH terms:
Haloperidol versus first‐generation antipsychotics for the treatment of schizophrenia and other psychotic disorders
1. Administration, Oral; 2. Antipsychotic Agents [adverse effects, *therapeutic use]; 3. Haloperidol [adverse effects, analogs & derivatives, *therapeutic use]; 4. Loxapine [adverse effects, therapeutic use]; 5. Psychotic Disorders [*drug therapy]; 6. Randomized Controlled Trials as Topic; 7. Schizophrenia [*drug therapy]; 8. Trifluoperazine [adverse effects, therapeutic use];
MESH terms:
Antidepressant treatment for postnatal depression
1. Antidepressive Agents, Second‐Generation [*therapeutic use]; 2. Clinical Trials as Topic; 3. Depression, Postpartum [*drug therapy]; 4. Fluoxetine [therapeutic use]; 5. Nortriptyline [therapeutic use]; 6. Paroxetine [therapeutic use]; 7. Randomized Controlled Trials as Topic; 8. Selective Serotonin Reuptake Inhibitors [*therapeutic use]; 9. Sertraline [therapeutic use];
MESH terms:
Flupenthixol versus low‐potency first‐generation antipsychotic drugs for schizophrenia
1. Akathisia, Drug‐Induced [etiology]; 2. Antipsychotic Agents [adverse effects, *therapeutic use]; 3. Chlorpromazine [adverse effects, *therapeutic use]; 4. Flupenthixol [adverse effects, *therapeutic use]; 5. Randomized Controlled Trials as Topic; 6. Schizophrenia [*drug therapy]; 7. Xerostomia [chemically induced];
MESH terms:
Fluphenazine versus low‐potency first‐generation antipsychotic drugs for schizophrenia
1. Akathisia, Drug‐Induced; 2. Antipsychotic Agents [adverse effects, *therapeutic use]; 3. Dyskinesia, Drug‐Induced; 4. Fluphenazine [adverse effects, *therapeutic use]; 5. Randomized Controlled Trials as Topic; 6. Schizophrenia [*drug therapy];
MESH terms:
Alternating current cranial electrotherapy stimulation (CES) for depression
1. Depression [*therapy]; 2. Electric Stimulation Therapy [*methods];
MESH terms:
Pharmacological interventions for preventing post‐traumatic stress disorder (PTSD)
1. Adrenergic beta‐1 Receptor Antagonists [therapeutic use]; 2. Amines [therapeutic use]; 3. Anti‐Anxiety Agents [therapeutic use]; 4. Anti‐Inflammatory Agents [therapeutic use]; 5. Antidepressive Agents, Second‐Generation [therapeutic use]; 6. Citalopram [therapeutic use]; 7. Cyclohexanecarboxylic Acids [therapeutic use]; 8. Gabapentin; 9. Hydrocortisone [therapeutic use]; 10. Propranolol [therapeutic use]; 11. Randomized Controlled Trials as Topic; 12. Stress Disorders, Post‐Traumatic [*prevention & control]; 13. Temazepam [therapeutic use]; 14. gamma‐Aminobutyric Acid [therapeutic use];
MESH terms:
Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders
1. Antipsychotic Agents [administration & dosage, therapeutic use]; 2. Delayed‐Action Preparations [administration & dosage, therapeutic use]; 3. Flupenthixol [administration & dosage, *analogs & derivatives, therapeutic use]; 4. Psychotic Disorders [*drug therapy]; 5. Randomized Controlled Trials as Topic; 6. Schizophrenia [*drug therapy]; 7. Tranquilizing Agents [administration & dosage, *therapeutic use];
MESH terms:
Pericyazine for schizophrenia
1. Akathisia, Drug‐Induced; 2. Antipsychotic Agents [adverse effects, *therapeutic use]; 3. Phenothiazines [adverse effects, *therapeutic use]; 4. Randomized Controlled Trials as Topic; 5. Schizophrenia [*drug therapy]; 6. Spasm [chemically induced]; 7. Tremor [chemically induced];
MESH terms:
Carbamazepine for schizophrenia
1. Antimanic Agents [*therapeutic use]; 2. Antipsychotic Agents [*therapeutic use]; 3. Carbamazepine [*therapeutic use]; 4. Combined Modality Therapy [methods]; 5. Randomized Controlled Trials as Topic; 6. Recurrence; 7. Schizophrenia [*drug therapy];
MESH terms:
Different regimens of intravenous sedatives or hypnotics for electroconvulsive therapy (ECT) in adult patients with depression
1. Anesthetics, Intravenous [*administration & dosage]; 2. Depression [*therapy]; 3. Electroconvulsive Therapy [*adverse effects]; 4. Epilepsy, Tonic‐Clonic [*complications]; 5. Etomidate [administration & dosage]; 6. Hypnotics and Sedatives [*administration & dosage]; 7. Methohexital [administration & dosage]; 8. Midazolam [administration & dosage]; 9. Propofol [administration & dosage]; 10. Randomized Controlled Trials as Topic; 11. Thiamylal [administration & dosage]; 12. Thiopental [administration & dosage];
MESH terms:
Sulpiride versus placebo for schizophrenia
1. Antipsychotic Agents [*therapeutic use]; 2. Placebos [therapeutic use]; 3. Randomized Controlled Trials as Topic; 4. Schizophrenia [*drug therapy]; 5. Sulpiride [*therapeutic use];
MESH terms:
General physical health advice for people with serious mental illness
1. *Health Status; 2. *Quality of Life; 3. Awareness; 4. Health Behavior; 5. Health Promotion [*methods]; 6. Mental Disorders [*complications, mortality]; 7. Randomized Controlled Trials as Topic; 8. Standard of Care;
MESH terms:
Metal protein attenuating compounds for the treatment of Alzheimer's dementia
1. Alzheimer Disease [*drug therapy]; 2. Amyloid beta‐Peptides [metabolism]; 3. Chelating Agents [adverse effects, *therapeutic use]; 4. Clioquinol [adverse effects, analogs & derivatives, *therapeutic use]; 5. Randomized Controlled Trials as Topic;
MESH terms:
Physical health care monitoring for people with serious mental illness
1. *Health Status; 2. *Quality of Life; 3. Disease Progression; 4. Mental Disorders [*complications];
MESH terms:
Respite care for people with dementia and their carers
1. Caregivers [*psychology]; 2. Dementia [*nursing, psychology]; 3. Randomized Controlled Trials as Topic; 4. Respite Care [*psychology]; 5. Stress, Psychological [*therapy]; 6. Therapeutic Touch;
MESH terms:
Perazine for schizophrenia
1. Antipsychotic Agents [adverse effects, *therapeutic use]; 2. Perazine [adverse effects, *therapeutic use]; 3. Randomized Controlled Trials as Topic; 4. Schizophrenia [*drug therapy];
MESH terms:
Chlorpromazine versus placebo for schizophrenia
1. Antipsychotic Agents [adverse effects, *therapeutic use]; 2. Chlorpromazine [adverse effects, *therapeutic use]; 3. Placebo Effect; 4. Randomized Controlled Trials as Topic; 5. Schizophrenia [*drug therapy, prevention & control]; 6. Secondary Prevention;
MESH terms:
Aripiprazole versus other atypical antipsychotics for schizophrenia
1. Antipsychotic Agents [*therapeutic use]; 2. Aripiprazole; 3. Benzodiazepines [therapeutic use]; 4. Piperazines [*therapeutic use]; 5. Quinolones [*therapeutic use]; 6. Randomized Controlled Trials as Topic; 7. Schizophrenia [*drug therapy];
MESH terms:
Anticholinergic medication for non‐clozapine neuroleptic‐induced hypersalivation in people with schizophrenia
1. Antipsychotic Agents [*adverse effects]; 2. Cholinergic Antagonists [*therapeutic use]; 3. Schizophrenia [*drug therapy]; 4. Sialorrhea [chemically induced, *drug therapy];
MESH terms:
Agomelatine versus other antidepressive agents for major depression
1. Acetamides [adverse effects, *therapeutic use]; 2. Antidepressive Agents [adverse effects, *therapeutic use]; 3. Depressive Disorder, Major [*drug therapy]; 4. Melatonin [agonists]; 5. Randomized Controlled Trials as Topic; 6. Selective Serotonin Reuptake Inhibitors [adverse effects, *therapeutic use];
MESH terms:
Quetiapine versus other atypical antipsychotics for schizophrenia
1. Antipsychotic Agents [adverse effects, *therapeutic use]; 2. Benzodiazepines [adverse effects, therapeutic use]; 3. Clozapine [adverse effects, therapeutic use]; 4. Dibenzothiazepines [adverse effects, *therapeutic use]; 5. Medication Adherence [statistics & numerical data]; 6. Olanzapine; 7. Piperazines [adverse effects, therapeutic use]; 8. Quetiapine Fumarate; 9. Randomized Controlled Trials as Topic; 10. Risperidone [adverse effects, therapeutic use]; 11. Schizophrenia [*drug therapy]; 12. Thiazoles [adverse effects, therapeutic use];
MESH terms:
Haloperidol versus placebo for schizophrenia
1. Akathisia, Drug‐Induced [etiology]; 2. Antipsychotic Agents [adverse effects, *therapeutic use]; 3. Dystonia [chemically induced]; 4. Haloperidol [adverse effects, *therapeutic use]; 5. Parkinsonian Disorders [chemically induced]; 6. Placebo Effect; 7. Randomized Controlled Trials as Topic; 8. Schizophrenia [*drug therapy]; 9. Treatment Outcome;
MESH terms:
Pimozide for schizophrenia or related psychoses
1. Antipsychotic Agents [*therapeutic use]; 2. Delusions [drug therapy]; 3. Pimozide [*therapeutic use]; 4. Psychotic Disorders [*drug therapy, psychology]; 5. Randomized Controlled Trials as Topic; 6. Recurrence; 7. Schizophrenia [*drug therapy]; 8. Schizophrenic Psychology;
MESH terms:
Dietary supplements for preventing postnatal depression
1. *Dietary Supplements; 2. Depression, Postpartum [*prevention & control]; 3. Docosahexaenoic Acids [*administration & dosage]; 4. Eicosapentaenoic Acid [*administration & dosage]; 5. Patient Dropouts [statistics & numerical data]; 6. Prenatal Care; 7. Randomized Controlled Trials as Topic; 8. Selenium [*administration & dosage];
MESH terms:
Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorder
1. Antimanic Agents [*therapeutic use]; 2. Benzodiazepines [therapeutic use]; 3. Bipolar Disorder [*drug therapy, prevention & control]; 4. Drug Therapy, Combination [methods]; 5. Lithium Compounds [therapeutic use]; 6. Olanzapine; 7. Randomized Controlled Trials as Topic; 8. Secondary Prevention; 9. Valproic Acid [*therapeutic use];
MESH terms:
Atypical antipsychotics for psychosis in adolescents
1. Antipsychotic Agents [adverse effects, *therapeutic use]; 2. Aripiprazole; 3. Benzodiazepines [adverse effects, therapeutic use]; 4. Molindone [adverse effects, therapeutic use]; 5. Olanzapine; 6. Piperazines [adverse effects, therapeutic use]; 7. Psychotic Disorders [*drug therapy]; 8. Quinolones [adverse effects, therapeutic use]; 9. Randomized Controlled Trials as Topic; 10. Risperidone [adverse effects, therapeutic use]; 11. Schizophrenia [drug therapy];
MESH terms:
Exercise for depression
1. Depression [*therapy]; 2. Exercise [*psychology]; 3. Psychotherapy; 4. Randomized Controlled Trials as Topic; 5. Treatment Outcome;
MESH terms:
Driving assessment for maintaining mobility and safety in drivers with dementia
1. *Safety; 2. Accidents, Traffic [*prevention & control]; 3. Automobile Driver Examination [*psychology]; 4. Dementia [*psychology]; 5. Transportation;
MESH terms:
Cognitive training and cognitive rehabilitation for mild to moderate Alzheimer's disease and vascular dementia
1. Alzheimer Disease [*rehabilitation]; 2. Cognitive Behavioral Therapy [*methods]; 3. Dementia, Vascular [*rehabilitation]; 4. Randomized Controlled Trials as Topic;
MESH terms:
Flow‐regulated versus differential pressure‐regulated shunt valves for adult patients with normal pressure hydrocephalus
1. Hydrocephalus, Normal Pressure [*surgery]; 2. Pressure; 3. Ventriculoperitoneal Shunt [*instrumentation, methods];
MESH terms:
Rivastigmine for vascular cognitive impairment
1. Cholinesterase Inhibitors [*therapeutic use]; 2. Dementia, Vascular [*drug therapy]; 3. Nootropic Agents [*therapeutic use]; 4. Phenylcarbamates [*therapeutic use]; 5. Rivastigmine;
MESH terms:
Quetiapine versus typical antipsychotic medications for schizophrenia
1. Antipsychotic Agents [adverse effects, *therapeutic use]; 2. Dibenzothiazepines [adverse effects, *therapeutic use]; 3. Patient Dropouts [statistics & numerical data]; 4. Quetiapine Fumarate; 5. Randomized Controlled Trials as Topic; 6. Schizophrenia [*drug therapy];
MESH terms:
Intermittent phototherapy versus continuous phototherapy for neonatal jaundice
1. Bilirubin; 2. Family; 3. *Jaundice, Neonatal; 4. Phototherapy;
MESH terms:
Volume‐targeted versus pressure‐limited ventilation in neonates
1. Bronchopulmonary Dysplasia [etiology, *prevention & control]; 2. Infant, Premature; 3. Intermittent Positive‐Pressure Ventilation [*methods, mortality]; 4. Pressure; 5. Randomized Controlled Trials as Topic; 6. Tidal Volume;
MESH terms:
Early planned removal of umbilical venous catheters to prevent infection in newborn infants
1. *Device Removal; 2. *Infant, Very Low Birth Weight; 3. *Umbilical Veins; 4. Catheter‐Related Infections [epidemiology, *prevention & control]; 5. Catheterization, Peripheral; 6. Catheters [*adverse effects]; 7. Cause of Death; 8. Central Venous Catheters; 9. Thrombosis [etiology]; 10. Time Factors;
MESH terms:
Cerebral near‐infrared spectroscopy monitoring for prevention of brain injury in very preterm infants
1. *Infant, Extremely Premature; 2. *Oxygen Consumption; 3. *Spectroscopy, Near‐Infrared; 4. Brain [*metabolism]; 5. Brain Injuries [*prevention & control]; 6. Randomized Controlled Trials as Topic;
MESH terms:
Sildenafil for pulmonary hypertension in neonates
1. Bronchodilator Agents [therapeutic use]; 2. Cause of Death; 3. Hypertension, Pulmonary [*drug therapy, mortality]; 4. Nitric Oxide [therapeutic use]; 5. Randomized Controlled Trials as Topic; 6. Sildenafil Citrate [*therapeutic use]; 7. Vasodilator Agents [*therapeutic use];
MESH terms:
Fluid supplementation for neonatal unconjugated hyperbilirubinaemia
1. *Phototherapy [methods, statistics & numerical data]; 2. Administration, Intravenous; 3. Administration, Oral; 4. Bilirubin [blood]; 5. Breast Feeding [statistics & numerical data]; 6. Cerebral Palsy [prevention & control]; 7. Exchange Transfusion, Whole Blood [statistics & numerical data]; 8. Fluid Therapy [*adverse effects, methods]; 9. Hyperbilirubinemia, Neonatal [blood, *therapy]; 10. Kernicterus [*prevention & control]; 11. Peristalsis; 12. Time Factors;
MESH terms:
Saline irrigation for the management of skin extravasation injury in neonates
1. Extravasation of Diagnostic and Therapeutic Materials [*therapy]; 2. Hyaluronoglucosaminidase [*therapeutic use]; 3. Medical Records; 4. Skin [*injuries]; 5. Sodium Chloride [*therapeutic use]; 6. Solutions; 7. Therapeutic Irrigation [methods];
MESH terms:
Antibiotics for neonates born through meconium‐stained amniotic fluid
1. *Amniotic Fluid; 2. Amikacin [therapeutic use]; 3. Ampicillin [therapeutic use]; 4. Anti‐Bacterial Agents [*therapeutic use]; 5. Bacterial Infections [*drug therapy, mortality, prevention & control]; 6. Gentamicins [therapeutic use]; 7. Incidence; 8. Length of Stay; 9. Meconium [*microbiology]; 10. Meconium Aspiration Syndrome [*drug therapy, epidemiology]; 11. Neonatal Sepsis [*drug therapy, mortality, prevention & control]; 12. Randomized Controlled Trials as Topic; 13. Respiration, Artificial [statistics & numerical data]; 14. Respiratory Insufficiency [epidemiology];
MESH terms:
Orotracheal intubation in infants performed with a stylet versus without a stylet
1. Gestational Age; 2. Infant, Premature; 3. Intensive Care Units, Neonatal [statistics & numerical data]; 4. Intubation, Intratracheal [instrumentation, *methods, statistics & numerical data]; 5. Pediatrics [statistics & numerical data];
MESH terms:
Clonidine for sedation and analgesia for neonates receiving mechanical ventilation
1. *Clonidine [administration & dosage, adverse effects]; 2. *Dexmedetomidine [administration & dosage, adverse effects]; 3. *Hypnotics and Sedatives [administration & dosage, adverse effects]; 4. *Respiration, Artificial; 5. Cause of Death; 6. Hospital Mortality; 7. Intensive Care Units, Neonatal [statistics & numerical data]; 8. Length of Stay [statistics & numerical data]; 9. Randomized Controlled Trials as Topic;
MESH terms:
Effects of targeting lower versus higher arterial oxygen saturations on death or disability in preterm infants
1. *Infant Mortality; 2. *Infant, Extremely Premature; 3. Age Factors; 4. Arteries; 5. Blindness [epidemiology, etiology]; 6. Cerebral Palsy [epidemiology]; 7. Enterocolitis, Necrotizing [epidemiology, etiology]; 8. Incidence; 9. Oximetry; 10. Oxygen [*administration & dosage, adverse effects, *blood]; 11. Publication Bias; 12. Randomized Controlled Trials as Topic; 13. Retinopathy of Prematurity [epidemiology, etiology, prevention & control]; 14. Selection Bias; 15. Software;
MESH terms:
Repeated lumbar or ventricular punctures in newborns with intraventricular haemorrhage
1. *Cerebral Ventricles; 2. *Punctures [adverse effects]; 3. *Spinal Puncture [adverse effects]; 4. Cerebral Hemorrhage [complications, mortality, *therapy]; 5. Conservative Treatment [adverse effects]; 6. Controlled Clinical Trials as Topic; 7. Hydrocephalus [etiology, *prevention & control]; 8. Infant, Premature; 9. Non‐Randomized Controlled Trials as Topic; 10. Randomized Controlled Trials as Topic; 11. Retreatment; 12. Ventriculoperitoneal Shunt [adverse effects];
MESH terms:
Frenotomy for tongue‐tie in newborn infants
1. Ankyloglossia [*surgery]; 2. *Breast Feeding [adverse effects]; 3. Gestational Age; 4. Lingual Frenum [*surgery]; 5. Mastodynia [etiology]; 6. Nipples; 7. Pain Measurement; 8. Randomized Controlled Trials as Topic;
MESH terms:
Neonatal vitamin A supplementation for the prevention of mortality and morbidity in term neonates in low and middle income countries
1. *Developing Countries; 2. *Infant Mortality; 3. *Morbidity; 4. Randomized Controlled Trials as Topic; 5. Vitamin A [*administration & dosage, adverse effects]; 6. Vitamin A Deficiency [prevention & control]; 7. Vitamins [*administration & dosage, adverse effects];
MESH terms:
Skin‐to‐skin care for procedural pain in neonates
1. Breast Feeding; 2. Heart Rate [physiology]; 3. Hydrocortisone [analysis]; 4. Infant, Premature; 5. Injections, Intramuscular [*adverse effects]; 6. Kangaroo‐Mother Care Method [*methods]; 7. Oxygen Consumption [physiology]; 8. Pain Management [*methods]; 9. Phlebotomy [*adverse effects]; 10. Punctures [*adverse effects]; 11. Randomized Controlled Trials as Topic; 12. Saliva [chemistry]; 13. Term Birth;
MESH terms:
Topical anaesthesia for needle‐related pain in newborn infants
1. *Anesthesia, Local [adverse effects, methods]; 2. Anesthetics, Local [*administration & dosage, adverse effects]; 3. Catheterization [adverse effects]; 4. Drug Combinations; 5. Infant, Premature; 6. Needles; 7. Pain [etiology, *prevention & control]; 8. Pain Measurement; 9. Phlebotomy [adverse effects]; 10. Punctures [*adverse effects]; 11. Randomized Controlled Trials as Topic; 12. Spinal Puncture [adverse effects]; 13. Tetracaine [*administration & dosage];
MESH terms:
Intravenous midazolam infusion for sedation of infants in the neonatal intensive care unit
1. Hypnotics and Sedatives [*administration & dosage, adverse effects]; 2. Infant, Premature; 3. Infusions, Intravenous; 4. Intensive Care Units, Neonatal; 5. Intensive Care, Neonatal; 6. Length of Stay; 7. Midazolam [*administration & dosage, adverse effects]; 8. Randomized Controlled Trials as Topic;
MESH terms:
Cromolyn sodium for the prevention of chronic lung disease in preterm infants
1. Chronic Disease; 2. Clinical Trials as Topic; 3. Cromolyn Sodium [*therapeutic use]; 4. Infant, Premature; 5. Infant, Premature, Diseases [mortality, *prevention & control]; 6. Lung Diseases [mortality, *prevention & control]; 7. Meta‐Analysis as Topic; 8. Respiratory System Agents [*therapeutic use];
MESH terms:
Body positioning for spontaneously breathing preterm infants with apnoea
1. Apnea [*therapy]; 2. Bradycardia [therapy]; 3. Infant, Premature; 4. Infant, Premature, Diseases [*therapy]; 5. Oxygen Consumption; 6. Patient Positioning [*methods]; 7. Posture [physiology]; 8. Randomized Controlled Trials as Topic; 9. Respiration;
MESH terms:
Nitric oxide for respiratory failure in infants born at or near term
1. Administration, Inhalation; 2. Extracorporeal Membrane Oxygenation; 3. Hernia, Diaphragmatic [complications]; 4. High-Frequency Ventilation; 5. Nitric Oxide [administration & dosage, *therapeutic use]; 6. Randomized Controlled Trials as Topic; 7. Respiratory Insufficiency [*drug therapy, mortality]; 8. Term Birth; 9. Vasodilator Agents [administration & dosage, *therapeutic use];
MESH terms:
Early administration of inhaled corticosteroids for preventing chronic lung disease in very low birth weight preterm neonates
1. *Infant, Very Low Birth Weight; 2. *Respiration, Artificial; 3. Administration, Inhalation; 4. Anti‐Inflammatory Agents [administration & dosage, *therapeutic use]; 5. Chronic Disease; 6. Glucocorticoids [administration & dosage, *therapeutic use]; 7. Infant, Premature; 8. Infant, Premature, Diseases [mortality, *prevention & control]; 9. Lung Diseases [mortality, *prevention & control]; 10. Randomized Controlled Trials as Topic; 11. Steroids [administration & dosage]; 12. Time Factors;
MESH terms:
Inhaled nitric oxide for respiratory failure in preterm infants
1. Administration, Inhalation; 2. Bronchopulmonary Dysplasia [mortality, prevention & control]; 3. Cerebral Hemorrhage [epidemiology, prevention & control]; 4. Incidence; 5. Infant, Premature; 6. Infant, Premature, Diseases [prevention & control, *therapy]; 7. Nitric Oxide [*administration & dosage]; 8. Randomized Controlled Trials as Topic; 9. Respiratory Insufficiency [*therapy]; 10. Salvage Therapy; 11. Vasodilator Agents [*administration & dosage];
MESH terms:
Heparin for the treatment of thrombosis in neonates
1. Anticoagulants [*therapeutic use]; 2. Heparin [*therapeutic use]; 3. Heparin, Low‐Molecular‐Weight [therapeutic use]; 4. Thrombosis [*drug therapy];
MESH terms:
Infant position in neonates receiving mechanical ventilation
1. Oxygen [metabolism]; 2. Patient Positioning [*methods]; 3. Prone Position; 4. Randomized Controlled Trials as Topic; 5. Respiration, Artificial [*methods]; 6. Supine Position;
MESH terms:
Synchronized mechanical ventilation for respiratory support in newborn infants
1. High-Frequency Ventilation [methods]; 2. Inhalation [physiology]; 3. Positive-Pressure Respiration [methods]; 4. Randomized Controlled Trials as Topic; 5. Respiration, Artificial [*methods];
MESH terms:
Responsive versus scheduled feeding for preterm infants
1. Enteral Nutrition [*methods, standards]; 2. Hunger [*physiology]; 3. Infant Nutritional Physiological Phenomena [*physiology]; 4. Infant, Premature [*physiology]; 5. Randomized Controlled Trials as Topic; 6. Satiation [physiology]; 7. Time Factors; 8. Weight Gain;
MESH terms:
Cup feeding versus other forms of supplemental enteral feeding for newborn infants unable to fully breastfeed
1. *Cooking and Eating Utensils; 2. Bottle Feeding; 3. Breast Feeding; 4. Enteral Nutrition [instrumentation, *methods]; 5. Infant, Premature; 6. Length of Stay;
MESH terms:
Early additional food and fluids for healthy breastfed full‐term infants
1. *Breast Feeding [statistics & numerical data]; 2. *Dietary Supplements [adverse effects]; 3. Dietary Carbohydrates [administration & dosage, adverse effects]; 4. Drinking Water [administration & dosage, adverse effects]; 5. Glucose [administration & dosage]; 6. Infant Food [*adverse effects]; 7. Randomized Controlled Trials as Topic; 8. Term Birth; 9. Time Factors;
MESH terms:
Instruments for assessing readiness to commence suck feeds in preterm infants: effects on time to establish full oral feeding and duration of hospitalisation
1. *Bottle Feeding; 2. *Breast Feeding; 3. *Infant, Premature; 4. *Sucking Behavior; 5. Hospitalization; 6. Time Factors;
MESH terms:
Sucrose for analgesia in newborn infants undergoing painful procedures
1. Administration, Oral; 2. Analgesics [*administration & dosage]; 3. Infant, Premature; 4. Pain [physiopathology, *prevention & control]; 5. Pain Measurement; 6. Punctures [adverse effects]; 7. Randomized Controlled Trials as Topic; 8. Sucrose [*administration & dosage];
MESH terms:
Epinephrine for transient tachypnea of the newborn
1. Adrenergic beta‐Agonists [*therapeutic use]; 2. Epinephrine [*therapeutic use]; 3. Oxygen Inhalation Therapy [statistics & numerical data]; 4. Randomized Controlled Trials as Topic; 5. Respiration, Artificial [statistics & numerical data]; 6. Transient Tachypnea of the Newborn [*drug therapy];
MESH terms:
Heparin for the prevention of intraventricular haemorrhage in preterm infants
1. *Cerebral Ventricles; 2. *Infant, Very Low Birth Weight; 3. Anticoagulants [*therapeutic use]; 4. Cerebral Hemorrhage [mortality, *prevention & control]; 5. Heparin [*therapeutic use]; 6. Infant, Premature; 7. Randomized Controlled Trials as Topic;
MESH terms:
Co‐bedding in neonatal nursery for promoting growth and neurodevelopment in stable preterm twins
1. *Beds; 2. *Twins; 3. Child Development [*physiology]; 4. Infant Care [*methods]; 5. Infant, Premature [*growth & development]; 6. Intensive Care Units, Neonatal; 7. Randomized Controlled Trials as Topic;
MESH terms:
Antimicrobial dressings for the prevention of catheter‐related infections in newborn infants with central venous catheters
1. *Bandages [adverse effects]; 2. Alginates [therapeutic use]; 3. Anti‐Bacterial Agents [therapeutic use]; 4. Anti‐Infective Agents [*therapeutic use]; 5. Catheter‐Related Infections [*prevention & control]; 6. Catheterization, Central Venous [*adverse effects]; 7. Central Venous Catheters [*adverse effects]; 8. Chlorhexidine [therapeutic use]; 9. Dermatitis, Contact [etiology]; 10. Ethanol [therapeutic use]; 11. Glucuronic Acid [therapeutic use]; 12. Hexuronic Acids [therapeutic use]; 13. Polyurethanes; 14. Povidone‐Iodine [therapeutic use]; 15. Randomized Controlled Trials as Topic; 16. Silver Compounds [therapeutic use];
MESH terms:
Antithrombin for the prevention of intraventricular hemorrhage in very preterm infants
1. *Infant, Extremely Premature; 2. Antithrombins [adverse effects, *therapeutic use]; 3. Cerebral Hemorrhage [mortality, *prevention & control]; 4. Cerebral Ventricles; 5. Infant, Premature, Diseases [mortality, *prevention & control]; 6. Randomized Controlled Trials as Topic;
MESH terms:
Frequency of endotracheal suctioning for the prevention of respiratory morbidity in ventilated newborns
1. *Catheter Obstruction; 2. *Intubation, Intratracheal; 3. *Respiration, Artificial; 4. Infant, Low Birth Weight; 5. Lung [metabolism]; 6. Randomized Controlled Trials as Topic; 7. Suction [*methods]; 8. Time Factors;
MESH terms:
Transcutaneous carbon dioxide monitoring for the prevention of neonatal morbidity and mortality
1. *Carbon Dioxide; 2. *Infant Mortality; 3. Blood Gas Monitoring, Transcutaneous [*methods]; 4. Morbidity;
MESH terms:
Alternative lipid emulsions versus pure soy oil based lipid emulsions for parenterally fed preterm infants
1. Bronchopulmonary Dysplasia [prevention & control]; 2. Emulsions; 3. Fatty Acids, Unsaturated; 4. Fish Oils [administration & dosage]; 5. gamma-Linolenic Acid [administration & dosage]; 6. *Infant, Premature; 7. Lipids [*administration & dosage]; 8. Olive Oil [administration & dosage]; 9. Parenteral Nutrition [*methods]; 10. Plant Oils [administration & dosage]; 11. Randomized Controlled Trials as Topic; 12. Retinopathy of Prematurity [prevention & control]; 13. Soybean Oil [*administration & dosage]; 14. Triglycerides [administration & dosage];
MESH terms:
Diuretics for transient tachypnoea of the newborn
1. Administration, Oral; 2. Cesarean Section [adverse effects]; 3. Diuretics [administration & dosage, *therapeutic use]; 4. Furosemide [administration & dosage, *therapeutic use]; 5. Injections, Intravenous; 6. Oxygen Inhalation Therapy [statistics & numerical data]; 7. Randomized Controlled Trials as Topic; 8. Transient Tachypnea of the Newborn [*drug therapy];
MESH terms:
Chest shielding for prevention of a haemodynamically significant patent ductus arteriosus in preterm infants receiving phototherapy
1. Ductus Arteriosus, Patent [*physiopathology]; 2. Infant, Extremely Premature; 3. Jaundice [*therapy]; 4. Phototherapy [*adverse effects]; 5. Radiation Protection [*methods]; 6. Randomized Controlled Trials as Topic; 7. Torso;
MESH terms:
Specialist teams for neonatal transport to neonatal intensive care units for prevention of morbidity and mortality
1. Infant Mortality; 2. *Intensive Care Units, Neonatal; 3. Patient Care Team [*organization & administration]; 4. *Specialization; 5. Transportation of Patients [*organization & administration];
MESH terms:
Rescue high‐frequency jet ventilation versus conventional ventilation for severe pulmonary dysfunction in preterm infants
1. *High‐Frequency Jet Ventilation; 2. *Infant, Premature; 3. *Infant, Very Low Birth Weight; 4. *Salvage Therapy; 5. Randomized Controlled Trials as Topic; 6. Respiration, Artificial; 7. Respiratory Distress Syndrome, Newborn [*therapy];
MESH terms:
Percutaneous central venous catheters versus peripheral cannulae for delivery of parenteral nutrition in neonates
1. *Infant, Newborn; 2. Catheterization, Central Venous [adverse effects, *instrumentation]; 3. Catheterization, Peripheral [adverse effects, *instrumentation]; 4. Extravasation of Diagnostic and Therapeutic Materials [etiology]; 5. Infant, Extremely Low Birth Weight; 6. Infant, Premature; 7. Infant, Very Low Birth Weight; 8. Parenteral Nutrition [adverse effects, *instrumentation]; 9. Randomized Controlled Trials as Topic;
MESH terms:
Antimicrobial‐impregnated central venous catheters for prevention of catheter‐related bloodstream infection in newborn infants
1. *Central Venous Catheters; 2. Anti‐Infective Agents [*administration & dosage]; 3. Catheter‐Related Infections [*prevention & control]; 4. Silver Compounds [*administration & dosage]; 5. Umbilical Veins; 6. Zeolites [*administration & dosage];
MESH terms:
Standardised formal resuscitation training programmes for reducing mortality and morbidity in newborn infants
1. *Infant Mortality; 2. Decision Support Techniques; 3. Program Evaluation [*standards]; 4. Randomized Controlled Trials as Topic; 5. Resuscitation [*education, standards];
MESH terms:
Intravenous in‐line filters for preventing morbidity and mortality in neonates
1. Catheterization, Peripheral [*instrumentation]; 2. *Drug Contamination; 3. Filtration [*instrumentation]; 4. Infant Mortality; 5. Infant, Premature; 6. Infusions, Intravenous [adverse effects, *instrumentation]; 7. Randomized Controlled Trials as Topic;
MESH terms:
Regional (spinal, epidural, caudal) versus general anaesthesia in preterm infants undergoing inguinal herniorrhaphy in early infancy
1. *Anesthesia, Conduction; 2. *Anesthesia, General; 3. Anesthesia, Epidural; 4. Anesthesia, Spinal; 5. Apnea [prevention & control]; 6. Bradycardia [prevention & control]; 7. Hernia, Inguinal [*surgery]; 8. Herniorrhaphy [*methods]; 9. Infant, Premature; 10. Infant, Premature, Diseases [*surgery]; 11. Postoperative Complications [prevention & control]; 12. Randomized Controlled Trials as Topic;
MESH terms:
Strategies for the discontinuation of humidified high flow nasal cannula (HHFNC) in preterm infants
1. *Infant, Premature; 2. Continuous Positive Airway Pressure [*methods]; 3. Device Removal [adverse effects, *methods]; 4. Humidifiers; 5. Noninvasive Ventilation [*methods]; 6. Ventilator Weaning [adverse effects, *methods];
MESH terms:
Elective high frequency oscillatory ventilation versus conventional ventilation for acute pulmonary dysfunction in preterm infants
1. *High‐Frequency Ventilation; 2. Chronic Disease; 3. Infant, Premature; 4. Infant, Premature, Diseases [*prevention & control]; 5. Lung Diseases [*prevention & control]; 6. Lung Injury [prevention & control]; 7. Randomized Controlled Trials as Topic; 8. Respiration, Artificial; 9. Respiratory Distress Syndrome, Newborn [therapy];
MESH terms:
Methods for securing endotracheal tubes in newborn infants
1. Equipment Safety; 2. Infant, Premature; 3. Intensive Care, Neonatal [methods]; 4. Intubation, Intratracheal [adverse effects, *instrumentation, methods]; 5. Randomized Controlled Trials as Topic; 6. Respiration, Artificial [instrumentation, methods];
MESH terms:
Home‐ versus hospital‐based phototherapy for the treatment of non‐haemolytic jaundice in infants at more than 37 weeks' gestation
1. *Home Care Services; 2. *Hospitalization; 3. Gestational Age; 4. Jaundice, Neonatal [*therapy]; 5. Phototherapy [*methods]; 6. Term Birth;